Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations - European Medical Journal

Shared Perspectives on Targeted Therapies for Metastatic BRAFV600 Mutations

Oncology

This session has been funded by Pierre Fabre; where the position and discussions may not represent the position of Pierre Fabre and the content is intended for healthcare professionals. Considering the nature of our discussion, please always consult your local Summary of Product Characteristics before making any prescription decisions.


 

Recorded live from Barcelona, Spain, during the 2024 European Society for Medical Oncology (ESMO) Congress, watch Egbert Smit discuss the latest advancements in treatment for BRAFV600-mutant metastatic non-small cell lung cancer (NSCLC). Also, hear from Axel Hauschild and Teresa Amaral as they provide an in-depth overview of the latest insights on targeted therapies for metastatic melanoma.

Speakers:

Egbert Smit1

Axel Hauschild2

Teresa Amaral3

1. Professor of Pulmonary Medicine (Pulmonary Oncology), and Head of the Department of Pulmonary Diseases, Leiden University Medical Centre (LUMC), and Department of Thoracic Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
2. Professor of Dermatology, University of Kiel, and Head of the Skin Cancer Trial Centre, University Hospital Schleswig-Holstein, Kiel, Germany
3. Consultant Medical Oncology and Head of Translational Research, Department of Dermatology, Skin Cancer Clinical Trials Centre, University Hospital and Faculty of Medicine, University of Tübingen, Germany

Rate this content's potential impact on patient outcomes

Thank you!

Please share some more information on the rating you have given